Molecular Heterogeneity, Biomarker Discovery, and Targeted Therapy in Asthma - Genomic Biomarkers for Pharmaceutical Development - page 90

[41] Naik PK, Bozyk PD, Bentley JK, Popova AP, Birch CM, Wilke CA, et al. Periostin promotes ibrosis and pre-
dicts progression in patients with Idiopathic Pulmonary Fibrosis. Am J Physiol Lung Cell Mol Physiol
2012;303(12):L1046-56.
[42] Kudo A. Periostin in ibrillogenesis for tissue regeneration: periostin actions inside and outside the cell. Cell
Mol Life Sci 2011;68:3201-7.
[43] Shikotra A, Choy DF, Ohri CM, Doran E, Butler C, Hargadon B, et al. Increased expression of immunoreactive
thymic stromal lymphopoietin in patients with severe asthma. J Allergy Clin Immunol 2012;129:104-111 e9.
[44] Choy DF, Modrek B, Abbas AR, Kummerfeld S, Clark HF, Wu LC, et al. Gene expression patterns of Th2
inlammation and intercellular communication in asthmatic airways. J Immunol 2011;186:1861-9.
[45] Wenzel SE, Schwartz LB, Langmack EL, Halliday JL, Trudeau JB, Gibbs RL, et al. Evidence that severe asthma
can be divided pathologically into two inlammatory subtypes with distinct physiologic and clinical character-
istics. Am J Respir Crit Care Med 1999;160:1001-8.
[46] Jia G, Erickson RW, Choy DF, Mosesova S, Wu LC, Solberg OD, et al. Periostin is a systemic biomarker of
eosinophilic airway inlammation in asthmatic patients. J Allergy Clin Immunol 2012;130:647-54 e10.
[47] St Ledger K, Agee SJ, Kasaian MT, Forlow SB, Durn BL, Minyard J, et al. Analytical validation of a highly
sensitive microparticle-based immunoassay for the quantitation of IL-13 in human serum using the Erenna
immunoassay system. J Immunol Methods 2009;350:161-70.
[48] van Wetering S, Zuyderduyn S, Ninaber DK, van Sterkenburg MA, Rabe KF, Hiemstra PS. Epithelial differen-
tiation is a determinant in the production of eotaxin-2 and -3 by bronchial epithelial cells in response to IL-4
and IL-13. Mol Immunol 2007;44:803-11.
[49] Hoshino M, Morita S, Iwashita H, Sagiya Y, Nagi T, Nakanishi A, et al. Increased expression of the
human Ca2+-activated Cl- channel 1 (CaCC1) gene in the asthmatic airway. Am J Respir Crit Care Med
2002;165:1132-6.
[50] Ben QW, Zhao Z, Ge SF, Zhou J, Yuan F, Yuan YZ. Circulating levels of periostin may help identify patients
with more aggressive colorectal cancer. Int J Oncol 2009;34:821-8.
[51] Sasaki H, Dai M, Auclair D, Fukai I, Kiriyama M, Yamakawa Y, et al. Serum level of the periostin, a homo-
logue of an insect cell adhesion molecule, as a prognostic marker in nonsmall cell lung carcinomas. Cancer
2001;92:843-8.
[52] Sasaki H, Lo KM, Chen LB, Auclair D, Nakashima Y, Moriyama S, et al. Expression of Periostin, homologous
with an insect cell adhesion molecule, as a prognostic marker in non-small cell lung cancers. Jpn J Cancer Res
2001;92:869-73.
[53] Sasaki H, Yu CY, Dai M, Tam C, Loda M, Auclair D, et al. Elevated serum periostin levels in patients with bone
metastases from breast but not lung cancer. Breast Cancer Res Treat 2003;77:245-52.
[54] Ignarro LJ. Nitric oxide as a unique signaling molecule in the vascular system: a historical overview. J Physiol
Pharmacol 2002;53:503-14.
[55] Taylor DR, Pijnenburg MW, Smith AD, De Jongste JC. Exhaled nitric oxide measurements: clinical application
and interpretation. Thorax 2006;61:817-27.
[56] Corren J. Inhibition of interleukin-5 for the treatment of eosinophilic diseases. Discov Med 2012;13:305-12.
[57] Walker W, Healey GD, Hopkin JM. RNA interference of STAT6 rapidly attenuates ongoing interleukin-13-me-
diated events in lung epithelial cells. Immunology 2009;127:256-66.
[58] Amerio P, Frezzolini A, Feliciani C, Verdolini R, Teofoli P, De Pita O, et al. Eotaxins and CCR3 receptor in
inlammatory and allergic skin diseases: therapeutical implications. Curr Drug Targets Inlamm Allergy
2003;2:81-94.
[59] Bochner BS, Bickel CA, Taylor ML, MacGlashan Jr. DW, Gray PW, Raport CJ, et al. Macrophage-derived
chemokine induces human eosinophil chemotaxis in a CC chemokine receptor 3- and CC chemokine receptor
4-independent manner. J Allergy Clin Immunol 1999;103:527-32.
[60] Hoersch S, Andrade-Navarro MA. Periostin shows increased evolutionary plasticity in its alternatively spliced
region. BMC Evol Biol 2010;10:30.
[61] Flood-Page P, Swenson C, Faiferman I, Matthews J, Williams M, Brannick L, et al. A study to evaluate safety and
eficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007;176:1062-71.
[62] Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to
measure asthma control. Eur Respir J 1999;14:902-7.
[63] Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al. Mepolizumab and exacerbations of
refractory eosinophilic asthma. N Engl J Med 2009;360:973-84.